sumatriptan has been researched along with moclobemide in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Mitchell, PB | 1 |
| Birk, KL; Cohen, AF; De Puy, ME; De Smet, M; Fisher, AL; Goldberg, MR; Musson, DG; Sterrett, A; Van Gerven, JM; Van Haarst, AD | 1 |
| de Bortoli, V; de Oliveira Sergio, T; Del-Ben, CM; Frias, AT; Gomes, RC; Matthiesen, M; Sant'Ana, AB; Vasconcelos, AT; Vilela-Costa, HH; Weffort, LF; Yamashita, PS; Zangrossi, H | 1 |
1 review(s) available for sumatriptan and moclobemide
| Article | Year |
|---|---|
Drug interactions of clinical significance with selective serotonin reuptake inhibitors.
Topics: Antidepressive Agents, Tricyclic; Benzamides; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Humans; Isoenzymes; Lithium; Liver; Moclobemide; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Selegiline; Sumatriptan; Tryptophan | 1997 |
1 trial(s) available for sumatriptan and moclobemide
| Article | Year |
|---|---|
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
Topics: Adult; Area Under Curve; Benzamides; Biotransformation; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Half-Life; Humans; Male; Methoxyhydroxyphenylglycol; Moclobemide; Monoamine Oxidase Inhibitors; Oxazoles; Oxazolidinones; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines | 1999 |
9 other study(ies) available for sumatriptan and moclobemide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Panic-modulating effects of alprazolam, moclobemide and sumatriptan in the rat elevated T-maze.
Topics: Alprazolam; Animals; Anti-Anxiety Agents; Brain; Disease Models, Animal; Escape Reaction; Exploratory Behavior; Fenclonine; Locomotion; Male; Maze Learning; Moclobemide; Panic; Rats; Rats, Wistar; Serotonin; Sumatriptan | 2016 |